Objective. Gout is characterized by recurrent attacks of arthritis with hyperuricaemia and urate crystalinduced inflammation. Although urate transporters are known as risk factors, the immunogenetics of gouty inflammation remains unclear. This study aimed to investigate the genetic association between immune/ metabolism regulators and gout.
Introduction
Gout is characterized by recurrent attacks of inflammatory arthritis with metabolic hyperuricaemia and deposition of urate crystals in articular and periarticular tissues [1, 2] . MSU crystals are recognized as danger signals that could induce the immune response, activate antigen-presenting cells and trigger infiltration of macrophages and neutrophils and cytokine cascades in gouty arthritis [3, 4] . Mechanistic studies revealed that urate crystals can activate the NLRP3 (nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3; also known as NALP3) inflammasome and caspase 1 (CASP1) in macrophages, resulting in the production of inflammatory IL-1b in gouty arthritis [57] .
Although the previous genome-wide association studies (GWAS) identified variants of urate transporters as important risk factors for hyperuricaemia and gout [8, 9] , there are limitations of GWAS [10] . The variants identified by GWAS and dysfunction of urate transporters cannot fully explain the pathogenesis of gouty arthritis, and only $10% of patients with hyperuricaemia develop gout [11] . Many people with hyperuricaemia never have inflammatory symptoms of gout. Furthermore, the acute attacks of gouty arthritis can be self-limited and spontaneously subside within a few days in some patient populations [14] . We proposed that in addition to urate transportasome, other factors able to regulate the metabolism and immune response may contribute to the pathogenesis of gouty arthritis.
In this study, we applied a candidate gene approach, screening the genetic association of gout with variants of NLRP3, CASP1, peroxisome proliferator-activated receptor-g (PPAR) and its coactivators. PPARg is a key regulator controlling both metabolism and inflammatory responses [12] , and increases in MSU crystal-stimulated macrophages [13] . Peroxisome proliferator-activated receptor-g coactivator 1a (PPARGC1A) and peroxisome proliferator-activated receptor-g coactivator 1b (PPARGC1B) are transcriptional coactivators of PPARg [14] . PPARGC1A regulates mitochondrial biogenesis, cellular cholesterol homoeostasis and inflammatory response [15] . PPARGC1B impedes the inflammatory cytokines IL-6 and IL-12, and inhibits macrophage-mediated inflammation [16] . PPARg, PPARGC1A and PPARGC1B all possess anti-inflammatory properties. In this study, we enrolled patients with recurrent attacks of gout to investigate the genetic association between gouty arthritis and variants of immune/metabolism regulators: NLRP3, CASP1, PPAR, PPARGC1A and PPARGC1B.
Methods

Patients
We enrolled a total of 448 patients with recurrent gouty arthritis from Chang Gung Memorial Hospital Health System in Taiwan from 2009 to 2014. The diagnosis of gouty arthritis used a set of clinical criteria, including the presence of urate crystals or tophi in joints and the frequencies of the attacks of acute arthritis. Only patients who had had more than three gout attacks or with chronic tophaceous gout were enrolled in this study. In addition, we recruited 943 healthy participants who had no selfreported gouty arthritis from a Taiwan biobank under a nationwide population study that comprises 9980 people of Han Chinese descent [17] . The controls were selected based on matched age and gender distribution of cases. This study was approved by the institutional review board of Chang Gung Memorial Hospital. Informed consent was obtained from each participant according to the Declaration of Helsinki.
Single nucleotide polymorphism genotyping, direct sequencing and haplotype analysis Genomic DNA was isolated from peripheral blood using the Gentra Puregene DNA purification kit (Qiagen, Hilden, Germany). In the initial screen, we examined a total of 71 single nucleotide polymorphisms (SNPs) (26 SNPs of NLRP3, 29 of PPAR, 4 of PPARGC1A, 11 of PPARGC1B and 1 of CASP1) using DNA samples of 94 cases from the 448 gout patients and 94 controls from the 943 population controls by MassArray assay (Sequenom, San Diego, CA, USA). The mean (S.D.) call rate of 71 SNP genotyping assays was 97.8% (1.98%). We excluded 49 SNPs for further analyses, because those had call rates <90%, non-polymorphism or P < 2.27 Â 10 À3 (0.05/22) (P value with the Bonferroni correction for multiple comparisons, P c < 0.05) in the HardyWeinberg equilibrium test for the dataset of 94 controls. SNP discovery for the associated gene was investigated by direct sequencing on the exons of PPARGC1B of DNA samples of 10 gout patients. SNP association was replicated and validated in all of the DNA samples of 448 cases and 943 controls by TaqMan assay (Life Technologies, Carlsbad, CA, USA). The TaqMan genotyping data of rs45520937 of the 94 individuals showed the concordance rate as 100% of that of the Sequenom MassArray assay. We analysed the linkage disequilibrium (LD) maps and haplotypes of genetic variants (rs10515638, rs10491360, rs45520937 and rs7712296) of PPARGC1B using the Haploview program (version 4.1), and PHASE 2.0 software. 0 ,6 0 -diamidino-2-phenylindole hydrochloride staining. Images were acquired with an Olympus FV1000 confocal microscope. ELISA was applied to detect the expression of IL-1b (R&D systems, Minneapolis, MN, USA) and TNFa (R&D systems). The assay sensitivity for IL-1b was 3.91 pg/ml, and for TNFa was 15.6 pg/ml. The experiments were done in triplicate.
Transfection and siRNA knockdown of PPARGC1B
The plasmid hPPARGC1B (Myc-DDK-tagged) containing full-length cDNA of PPARGC1B was obtained from Origene (Rockville, MD, USA). The PPARGC1B gene was knocked down by ON-TARGETplus siRNA SMARTpool (Dharmacon, Thermo Fisher Scientific, Lafayette, CO, USA). Site-direct mutagenesis on the A allele of rs45520937 of PPARGC1B cDNA was performed using the QuickChange kit (Stratagene, La Jolla, CA, USA). The THP-1 cells (1 Â 10 6 cells/well) were differentiated to macrophages by culturing with phorbol myristyl acetate (0.1 mM), and then transfected by (i) plasmids containing PPARGC1B full-length cDNA with G or A variant of rs45520937, (ii) PPARGC1B siRNA, (iii) vector only or (iv) scramble siRNA, using a liposome system (Lipofectamine 2000, Life Technologies). The cells were incubated with MSU crystals (100 mg/ml) for 24 h. The cell lysate and supernatant were collected, and subjected to gene expression analyses by real-time quantitative PCR and ELISA. Each experiment was done in triplicate.
Statistical analysis
The data are reported as means, medians and standard error of the mean (S.E.M.), ranges or percentages, as appropriate. The difference of SNP frequencies between the cases and controls was compared using Fisher's exact test. The genotype distribution was examined by logistic regression using IBM SPSS Statistics version 22.0 (IBM, Armonk, NY, USA). Bonferroni's correction was applied for the multiple comparisons. The odds ratios (ORs) were calculated using Haldane's modification, which added 0.5 to all cells to accommodate possible zero counts. The concentrations of cytokines and folds of gene expression were compared between groups using Student's t-tests. We performed Fisher's exact tests, Bonferroni's correction, Student's t-test and the OR calculation using MATLAB version 8.1 and Statistics Toolbox version 8.2 (MathWorks, Natick, MA, USA). The statistical significance was defined as P < 0.05. All of the P-values were two-tailed.
Results
Demographic variables and clinical characteristics of the enrolled subjects
We enrolled 448 gout patients and 943 population controls from Taiwan, where 98% of the population is made up of Han Chinese. The demographic data of 448 gout patients and 943 population controls are summarized in Table 1 . Age and gender showed no difference between cases and controls (P = 0.759 and 0.064, respectively). Table S1 , available at Rheumatology Online). Comparing the allele frequencies between the cases and controls, we identified 10 SNPs with P < 0.05, which included six intronic SNPs of PPAR (rs10510410, rs10510411, rs10510412, rs10510417, rs2938392 and rs2292101) and four SNPs of PPARGC1B (two intronic SNPs: rs10515638 and rs10491360; one missense SNP: rs45520937; and SNP rs77122961 on the 3 0 -untranslational region) ( Table 2 and Supplementary Table S2 , available at Rheumatology Online). After Bonferroni's correction, three SNPs (rs10491360, rs45520937 and rs7712296) of PPARGC1B still exhibited statistical significance (Table 2) . Notably, the significant variants included a missense SNP, rs45520937, which causes Arg265Gln (p.R265Q) substitution in the exon 5 of PPARGC1B. When comparing the allele frequencies between cases and controls, the missense SNP rs45520937 showed a P-values of 8 Table 2) .
We performed statistical power analysis at different levels of significance and genotype relative risk according to data of the initial screen of 188 samples based on genetic models of rs45530927 under the 6.24% of prevalence of gouty arthritis in Taiwan [22] . Supplementary Fig. S1A , available at Rheumatology Online, shows the power curves for the test of genotypic association as a function of sample size under different significance levels. Supplementary Fig. S1B , available at Rheumatology Online, presents the power curves in the range of genotype relative risk for heterozygous Aa genotype (GRR Aa ) (1.52.7) and genotype relative risk for risk homologous AA genotype (GRR AA ) (3.04.2) at the significant P-values of 0.001. In this study, the enrolled participants comprising 448 cases and 943 controls were sufficient to achieve a power of at least 0.9 as GRR Aa of 1.9 and GRR AA of 3.3 with a significance level of P < 0.001 ( Supplementary Fig. S1B , available at Rheumatology Online).
LD of the four SNPs (rs10515638, rs10491360, rs45520937 and rs7712296) of PPARGC1B was evaluated using the genotyping data of 94 gout patients. A strong LD was found between rs45520937 and rs7712296. Five haplotypes were inferred from rs10491360, rs45520937 and rs7712296, and haplotype 1 was the most common one created by the three wild-type alleles (TGC). The two risk alleles, A of rs45520937 and A of rs7712296, were found in 31.4% of the inferred haplotypes ( Supplementary  Fig. S2 , available at Rheumatology Online). These results suggest that the missense SNP rs45520937 could be as a representative risk SNP in this LD region of PPARGC1B for gouty arthritis.
Replication and combined-samples analyses confirmed the association between the missense variant rs45520937 of PPARGC1B and gout Replication and combined-samples analyses further confirmed the strong association between the risk A allele of rs45520937 of PPARGC1B and gouty arthritis [P = 6.66 Â 10 À9 , OR (95% CI): 1.85 (1.51, 2.28)] ( Table 3 ). The recessive model (genotype GG/GA vs AA of rs45520937) also displayed a significant association [P = 4.60 Â 10
À3
; OR (95% CI): 2.74 (1.38, 5.44)] (Table 3) . To exclude confounding factors, we examined the association between SNP re45520937 and hyperuricaemia or different comorbidities including renal deficiency (eGFR < 30) [21] , hypertension [18] , hyperlipidaemia [19] and diabetes mellitus [20] by logistic regression analysis adjusting for gender, BMI and the use of urate-lowering therapy. When comparing the genotype frequencies of SNP re45520937 in patients with the comorbidities in a The definitions of the medical terms and diseases were set according to the criteria of the following references: hyperuricaemia [1] , eGFR [21] , hypertension [18] , hyperlipidaemia [19] and diabetes mellitus [20] . ND: data not determined. dominant model, none of the diseases showed significant association with rs45520937 (Table 4) . These data indicate that SNP re45520937 is statistically associated with gouty arthritis, but not hyperuricaemia or the comorbidities.
Induction of PPARGC1B and NLRP3 expression in macrophages, PBMCs and synovial cells of gout patients Upon the stimulation of MSU crystals, activated THP-1 macrophages produced IL-1b (Fig. 1A) , and increasingly expressed the mRNA of PPAR, PPARGC1B and NLRP3 (Fig.  1B) . Compared with the medium controls, the related levels of PPAR, PPARGC1B and NLRP3 mRNA were up-regulated to 1.70-, 3.19-and 2.09-fold, respectively, in the THP-1 macrophages stimulated by urate crystals of 500 mg/ml (Fig. 1B) . Furthermore, siRNA knockdown of PPARGC1B caused a significant increase of NLRP3 mRNA in THP-1 macrophages (Fig. 1C) . The expression of PPARGC1B and NLRP3 was examined in the PBMCs and synovial cells by immunofluorescence assay. Compared with the cells from patients in non-active stage, increased expression of PPARGC1B and NLRP3 proteins was detected in the PBMCs of gout patients in the active stage ( Fig. 1D and E). Confocal microscopy revealed strong expression and colocalization of PPARGC1B and NLRP3 proteins in the synovial cells of gout patients in the active stage (Fig. 1F) .
The risk A allele of rs45520937 of PPARGC1B augmented IL-1b and NLRP3 in gout The gene expression of PPAR, PPARGC1B and NLRP3 was determined by real-time quantitative PCR using RNA of PBMCs isolated from the gout patients with GG genotype (n = 38), or GA/AA genotypes (n = 35) of rs45520937 ( Fig. 2A) . When comparing with the GG genotype carriers, subjects with GA/AA genotypes showed a 1.42-fold higher level of PPARGC1B (P = 0.003), and 1.57-fold increased amount of NLRP3 (P = 0.044) (Fig. 2A) . Compared with the GG genotype carriers, plasma IL-1b showed a statistical increase in gout patients with GA/AA genotypes (P = 0.006) (Fig. 2B) . When subgrouping the plasma samples according to the collection time of the disease status, significant higher levels of plasma IL-1b were noticed in GA/AA genotype carriers (n = 12) [mean (S.E.M.): 3.87 pg/ mL (1.08)] than that of GG genotype subjects (n = 15) [1.32 pg/mL (0.29)] (P = 0.042) for gout patients in the active stage (Fig. 2C) . These data suggest that the risk A allele of rs45520937 of PPARGC1B is associated with the increased expression of NLRP3, and higher levels of plasma IL-1b in gouty arthritis.
We transfected the plasmids containing full-length PPARGC1B cDNA with wild-type G or risk A allele of rs45520937 into THP-1 cells, and measured the expression of NLRP3 mRNA and production of IL-1b. The amounts of NLRP3 mRNA showed no difference between the transfectants of wild-type plasmid and the vector control (Fig. 2D) . However, NLRP3 mRNA significantly increased in the transfectants of PPARGC1B cDNA with the risk A allele of rs45520937 variant [mean (S.E.M.): (Fig. 2E) . These data suggest that the risk A allele of rs45520937 of PPARGC1B augments NLRP3 inflammasome and IL1-b production.
Discussion
To the best of our knowledge, this is the first study providing the functional link of genetic variants of PPARGC1B, an anti-inflammatory mediator, to gouty arthritis. In this study, we identified that three SNPs (rs10491360, rs45520937 and rs7712296) of PPARGC1B showed significant association with gouty arthritis. Notably, the missense variant rs45520937 (p.R265Q) in the exon 5 of PPARGC1B served as a representative The definitions of the medical terms and diseases were set according to the criteria in the following references: hyperuricaemia [1] , eGFR [21] , hypertension [18] , hyperlipidaemia [19] and diabetes mellitus [20] . b P-values and the b coefficients were adjusted for gender, BMI and the use of urate-lowering therapy by logistic regression analysis. . PPARGC1B was up-regulated and co-localized with the NLRP3 inflammasome in the active macrophages, PBMCs and synovial cells of patients with gouty arthritis. Gout patients carrying the risk A allele of the rs45520937 variant had up-regulated NLRP3 and plasma IL-1b. Furthermore, transfectants of PPARGC1B rs45520937 A allele significantly increased NLRP3 and production of IL-1b in MSUactivated THP-1 macrophages. These data indicate that the missense variant rs45520937 of PPARGC1B augments the NLRP3 inflammasome response, leads to the up-regulation of inflammatory cytokine IL-1b production and contributes to the pathogenesis of gouty arthritis.
Previous GWAS revealed that the main genetic determinants of gout were variants of urate transporters [2325] . However, GWAS have been criticized for the limitations of identification of weakly contributing loci, the lack of ability to detect rare variants or functional exonic alleles and low reproducibility across studies or populations [10, 24, 26] . Association between gout and immune-related genes may be overwhelmed by the variations of transporters in GWAS. The resolution to overcome the limitations of GWAS is provided by genotyping and exomic sequencing of the candidate genes/region, or wholeexome/whole-genome sequencing [24, 27] . Our study is the first to report the genetic association between a missense variant of immunoregulator PPARGC1B gouty arthritis and provide the functional link. The allele frequencies of the missense variant rs45520937 of PPARGC1B are low ($27%) in other ethnic populations. The genetic association identified in this study requires replication by others. More studies are needed to validate our results and to investigate the underlying mechanism.
The NLRP3 inflammasome plays important roles in many diseases [28, 29] . Urate crystals and hyperuricaemia induce NLRP3 activation in macrophages in metabolic diseases [3032] . Mutations in NLRP3 have been noticed in familial inflammatory diseases [3335] . Because NLRP3 plays a critical role in the pathogenesis of gout, we screened the genetic association of 26 SNPs (including 22 missense variants) of NLRP3. However, 96% (25/26) of the screened NLRP3 SNPs showed non-polymorphism in our gout patients. Consistent with our results, Meng et al. [36] reported that none of 17 tagSNPs of the NLRP3 gene was associated with gouty arthritis. McKinney et al. and TNXIP, to examine their association with gouty arthritis. They found that none of three variants (rs10754558, rs35829419 and rs7512998) of the NLRP3 gene was associated with gout in European or Polynesian populations [37] . In addition, the previous GWAS failed to find significant association between NLRP3 variants and gouty arthritis [23, 25] . We proposed that instead of NLRP3, other immune/metabolism regulators are involved in gouty inflammation.
PPARGC1B variants have been linked to many immune/ metabolic diseases, including AS, type II diabetes, metabolic syndrome, obesity, airway hypersensitivity and breast cancer [3841] . In the previous GWAS of autoimmune diseases, a missense variant rs11959820 of PPARGC1B showed significant association with AS in patients of Western European descent [42, 43] . Recently, a candidate gene-based study described that SNP rs7379457 in the promoter of PPARGC1B was statistically associated with ankylosing spondylitis (P = 0.005) [42, 44] . In addition, the rs45520937 of PPARGC1B was reported to be associated with airway hypersensitivity of patients with asthma [41, 45] . In our study, we found that the missense variant rs45520937 was significantly associated with gout, but not comorbidities, for example, obesity or diabetes. Consistent with our results, rs45520937 showed no association with obesity and type II diabetes in a Danish population [46] . These results suggest that PPARGC1B variants contribute to the regulation and extent of inflammation.
PPARGC1B plays critical roles in the regulation of mitochondrial biogenesis, fatty acid b-oxidation and macrophage-mediated inflammation [16] . In this study, we demonstrated that siRNA knockdown of PPARGC1B resulted in the up-regulation of NLRP3, suggesting that PPARGC1B is required for the suppression of the NLRP3 inflammasome in urate crystal-induced inflammation. In addition, the SNP rs45520937 of PPARGC1B may influence the risk of gout via regulating urate levels. Szatmari et al. [47] reported that the responsive elements of PPARgretinoid X receptors were the upstream enhancers of ABCG2 (ATP-binding cassette transporter, subfamily G, member 2), a urate transporter. The missense SNP rs45520937 (+102525G > A, R265Q) may cause conformational change of PPARGC1B protein, a functional coactivator of PPARgretinoid X receptors. Such structural modification may lead to interference in its interaction with the ligand-dependent transcription factors (e.g. PPARg), and the repression of the function of PPARGC1B and PPARg [41, 45] .
In conclusion, patients with the PPARGC1B variants have increased risks of gout development. The missense variant rs45520937 of PPARGC1B augments the NLRP3 inflammasome and increases plasma IL-1b, suggesting that PPARGC1B variants contribute to the pathogenesis of gout inflammation. Variants of PPARGC1B have the potential to be biomarkers and therapeutic targets for NLRP3-mediated inflammation in gouty arthritis.
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